文献速递骨软组织肉瘤与黑色素瘤

纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤:I期剂量递增研究更新生存、缓解与安全性数据

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
PubMed 文献 · J Clin Oncol · 2017-10-17

该I期剂量递增研究CA209-004报告了纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的长期随访数据。在所有同期队列(N=94)中,3年OS率为63%,中位OS未达到,客观缓解率为42%,中位缓解持续时间为22.3个月,3-4级治疗相关不良事件发生率为59%。

要点

  • 所有同期队列(N=94)3年OS率为63%,中位OS未达到。
  • 客观缓解率42%,中位缓解持续时间22.3个月。
  • 3-4级治疗相关不良事件发生率59%,最常见为脂肪酶升高(15%)。

核心结论

  • 这是纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的最长随访数据。
  • 3年OS率63%是该患者人群中观察到的最高值,为免疫检查点抑制剂在晚期黑色素瘤中的持久临床活性提供了额外证据。

研究设计与样本

  • I期剂量递增研究CA209-004,同期队列1、2、2a和3接受递增剂量的纳武利尤单抗联合伊匹木单抗每3周一次共4次,随后纳武利尤单抗每3周一次共4次,然后纳武利尤单抗联合伊匹木单抗每12周一次共8次。
  • 扩展队列(队列8)接受纳武利尤单抗1 mg/kg联合伊匹木单抗3 mg/kg每3周一次共4次,随后纳武利尤单抗3 mg/kg每2周一次。
  • 所有同期队列共94例患者,随访时间30.3至55.0个月。

主要发现

  • 所有同期队列(N=94)3年OS率为63%,中位OS未达到。
  • 按改良WHO标准,客观缓解率为42%,中位缓解持续时间为22.3个月。
  • 3级和4级治疗相关不良事件发生率为59%。
  • 最常见的3级和4级治疗相关不良事件为脂肪酶升高(15%)、丙氨酸氨基转移酶升高(12%)和天冬氨酸氨基转移酶升高(11%)。
  • 发生1例治疗相关死亡(1.1%),该患者在末次纳武利尤单抗联合伊匹木单抗给药后70天出现多器官衰竭。

临床怎么用

  • 队列8所用纳武利尤单抗1 mg/kg联合伊匹木单抗3 mg/kg每3周一次共4次、随后纳武利尤单抗3 mg/kg每2周一次的剂量和方案已在II期和III期研究中使用,现获批用于不可切除或转移性黑色素瘤患者。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose The clinical activity observed in a phase I dose-escalation study of concurrent therapy with nivolumab (NIVO) and ipilimumab (IPI) in patients with previously treated or untreated advanced melanoma led to subsequent clinical development, including randomized trials. Here, we report long-term follow-up data from study CA209-004, including 3-year overall survival (OS). Patients and Methods Concurrent cohorts 1, 2, 2a, and 3 received escalating doses of NIVO plus IPI once every 3 weeks for four doses, followed by NIVO once every 3 weeks for four doses, then NIVO plus IPI once every 12 weeks for eight doses. An expansion cohort (cohort 8) received concurrent NIVO 1 mg/kg plus IPI 3 mg/kg once every 3 weeks for four doses, followed by NIVO 3 mg/kg once every 2 weeks, which is the dose and schedule used in phase II and III studies and now approved for patients with unresectable or metastatic melanoma. Results Among all concurrent cohorts (N = 94) at a follow-up of 30.3 to 55.0 months, the 3-year OS rate was 63% and median OS had not been reached. Objective response rate by modified WHO criteria was 42%, and median duration of response was 22.3 months. Incidence of grade 3 and 4 treatment-related adverse events was 59%. The most common grade 3 and 4 treatment-related adverse events were increases in lipase (15%), alanine aminotransferase (12%), and aspartate aminotransferase (11%). One treatment-related death (1.1%) occurred in a patient who had multiorgan failure 70 days after the last dose of NIVO plus IPI. Conclusion This is the longest follow-up for NIVO plus IPI combination therapy in patients with advanced melanoma. The 3-year OS rate of 63% is the highest observed for this patient population and provides additional evidence for the durable clinical activity of immune checkpoint inhibitors in the treatment of advanced melanoma.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Callahan MK, Kluger H, Postow MA, et al. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. J Clin Oncol. 2017. PMID: 29040030. doi:10.1200/JCO.2017.72.2850

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。